To overcome these difficulties as much as possible, our studies initially assessed the anti-tumor effectiveness of miR-96-5p in genetic approaches (knockout and overexpression), subsequently examined its effectiveness using a drug delivery system based on AAV-PAN viruses [34], and provided evidence that the AAV-PAN system can partially target pancreatic tumors. The gene discussed is ADA2; the disease is pancreatic neoplasm.